MedTrace Logo

Validation of Clara Cell Protein as a Novel Diagnostic Biomarker for the Differentiation of Cardiogenic Pulmonary Edema From Non-Cardiogenic Pulmonary Edema

NCT07338227 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-01-13

No results posted yet for this study

Summary

This study aimed to validate the use of clara cell secretory protein (CC16) as a biomarker for differentiating between cardiogenic pulmonary edema (CPE) and non-cardiogenic pulmonary edema (NCPE).

Conditions

  • Clara Cell Protein
  • Diagnostic Biomarker
  • Differentiation
  • Cardiogenic Pulmonary Edema
  • Non-Cardiogenic Pulmonary Edema

Interventions

OTHER

Clara cell protein 16

Clara cell protein 16 (CC16) concentration was measured in serum samples drawn within 24 hours of intubation.

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-01-01
Completion
2024-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07338227 on ClinicalTrials.gov